Bashir M Mohamed
Overview
Explore the profile of Bashir M Mohamed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bates M, Mohamed B, Lewis F, OToole S, OLeary J
Biochim Biophys Acta Rev Cancer
. 2024 Nov;
1879(6):189224.
PMID: 39581234
High-grade serous ovarian cancer (HGSC) is the most common subtype of ovarian cancer. HGSC patients typically present with advanced disease, which is often resistant to chemotherapy and recurs despite initial...
2.
Kelly T, Spillane C, Ward M, Hokamp K, Huang Y, Tewari P, et al.
Front Cell Dev Biol
. 2023 Dec;
11:1150991.
PMID: 38143926
High-grade serous ovarian cancer (HGSOC) is the most prevalent and deadliest subtype of epithelial ovarian cancer (EOC), killing over 140,000 people annually. Morbidity and mortality are compounded by a lack...
3.
Alharbi B, Qanash H, Binsaleh N, Alharthi S, Elasbali A, Gharekhan C, et al.
Sci Rep
. 2023 May;
13(1):7462.
PMID: 37156818
Immunotherapies, including immune checkpoint inhibitors, have limitations in their effective treatment of malignancies. The immunosuppressive environment associated with the tumor microenvironment may prevent the achievement of optimal outcomes for immune...
4.
Elasbali A, Abu Al-Soud W, Mousa Elayyan A, Al-Oanzi Z, Alhassan H, Mohamed B, et al.
J Biomol Struct Dyn
. 2023 Mar;
41(23):14135-14151.
PMID: 36943780
Traditional treatment of cancer has been plagued by a number of obstacles, such as multiple drug resistance, toxicity and financial constraints. In contrast, phytochemicals that modulate a variety of molecular...
5.
Mohamed B, Ward M, Bates M, Spillane C, Kelly T, Martin C, et al.
Sci Rep
. 2023 Mar;
13(1):3704.
PMID: 36879003
Circulating tumour cells (CTCs) are a critical intermediate step in the process of cancer metastasis. The reliability of CTC isolation/purification has limited both the potential to report on metastatic progression...
6.
Bates M, Mohamed B, Ward M, Kelly T, OConnor R, Malone V, et al.
Biochim Biophys Acta Rev Cancer
. 2023 Feb;
1878(2):188863.
PMID: 36796527
This review is an overview of the current knowledge regarding circulating tumour cells (CTCs), which are potentially the most lethal type of cancer cell, and may be a key component...
7.
Elasbali A, Abu Al-Soud W, Alhassan H, Mousa Elayyan A, Kamal M, Alanazi H, et al.
J Biomol Struct Dyn
. 2023 Jan;
41(22):12789-12797.
PMID: 36644886
Sphingosine kinase 1 (SphK1) dysfunction is well-known to be linked to various severe diseases, including breast, lung, prostate, and hematological cancers. Due to its crucial function in the onset of...
8.
Ward M, Kane L, Norris L, Mohamed B, Kelly T, Bates M, et al.
Mol Cancer
. 2021 Apr;
20(1):59.
PMID: 33789677
Cancer cells that transit from primary tumours into the circulatory system are known as circulating tumour cells (CTCs). These cancer cells have unique phenotypic and genotypic characteristics which allow them...
9.
Mohamed B, Boyle N, Schinwald A, Murer B, Ward R, Mahfoud O, et al.
Sci Rep
. 2018 Jan;
8(1):679.
PMID: 29330439
Citrullination, or the post-translational deimination of polypeptide-bound arginine, is involved in several pathological processes in the body, including autoimmunity and tumorigenesis. Recent studies have shown that nanomaterials can trigger protein...
10.
Di Cristo L, Movia D, Bianchi M, Allegri M, Mohamed B, Bell A, et al.
Toxicol Sci
. 2015 Nov;
150(1):40-53.
PMID: 26612840
Amorphous silica nanoparticles (ASNP) can be synthetized via several processes, 2 of which are the thermal route (to yield pyrogenic silica) and the wet route from a solution containing silicate...